Osteoporosis therapeutics market is expected to change

Osteoporosis therapeutics market is expected to change. As patent of original drugs expires which occupied most portion of the market, struggle for lead seems to become fierce.

Fosamax Plus D recorded prescription cost of 7.7 billion won in the first half of 2013 which decreased by 10.5% due to release of generic drug. Fosamax Plus recorded prescription cost of 1.6 billion won and -15.7% growt...